Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3 by Damgaard, Dres et al.
 
  
 
Aalborg Universitet
Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for
anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3
Damgaard, Dres; Bawadekar, Mandar; Senolt, Ladislav; Stensballe, Allan; Shelef, Miriam A;
Nielsen, Claus H
Published in:
PLOS ONE
DOI (link to publication from Publisher):
10.1371/journal.pone.0203214
Creative Commons License
CC0 1.0
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Damgaard, D., Bawadekar, M., Senolt, L., Stensballe, A., Shelef, M. A., & Nielsen, C. H. (2018). Relative
efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein
antibodies in fibrinogen, alpha-enolase and histone H3. PLOS ONE, 13(8), [e0203214].
https://doi.org/10.1371/journal.pone.0203214
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
RESEARCH ARTICLE
Relative efficiencies of peptidylarginine
deiminase 2 and 4 in generating target sites
for anti-citrullinated protein antibodies in
fibrinogen, alpha-enolase and histone H3
Dres Damgaard1,2*, Mandar Bawadekar3, Ladislav Senolt4, Allan Stensballe5, Miriam
A. Shelef3,6, Claus H. Nielsen1,2
1 Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University
Hospital, Rigshospitalet, Copenhagen, Denmark, 2 Section for Periodontology, Microbiology and Community
Dentistry, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark, 3 Department of Medicine, University of Wisconsin, Madison, Wisconsin, United
States of America, 4 Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine,
Charles University, Prague, Czech Republic, 5 Department of Health Science and Technology, Aalborg
University, Aalborg, Denmark, 6 William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin,
United States of America
* dres.damgaard@regionh.dk
Abstract
Objective
Peptidylarginine deiminase 2 (PAD2) and PAD4 are expressed in the synovium of rheuma-
toid arthritis (RA) patients and catalyze citrullination of arginine residues in proteins targeted
by anti-citrullinated protein antibodies (ACPAs). Little is known about the relative importance
of PAD2 and PAD4 in generating citrullinated self-antigens. Here we investigate the ability
of PAD2 and PAD4 to generate citrullinated targets for ACPAs in four human proteins.
Methods
Synovial fluid (SF) and plasma were collected from 42 RA patients. Human fibrinogen,
human alpha-enolase (ENO1), human histone H3, and human serum albumin (HSA) were
citrullinated in vitro by PAD2 or PAD4. The total degree of citrullination was determined
using the anti-modified citrulline approach. Antibody binding to native and citrullinated pro-
teins was measured by ELISA.
Results
ACPAs within pooled SF from multiple RA patients reacted equally well with, and cross-
reacted with, PAD2- and PAD4-citrullinated fibrinogen. ACPAs from most individual patient
SF and plasma samples bound equally well to PAD2- and PAD4-citrullinated fibrinogen or
ENO1. When histone H3 was used as target, PAD4 was generally superior in generating
epitopes recognized by ACPAs. No binding to citrullinated HSA was observed.
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Conclusion
In most patients, PAD2 and PAD4 are equally efficient in generating citrullinated target sites
for ACPAs in fibrinogen and ENO1. The binding of autoantibodies to histone H3 was gener-
ally higher after citrullination with PAD4 than with PAD2. Citrullinated HSA is not a target for
ACPAs.
Background
Production of anti-citrullinated protein antibodies (ACPAs) characterizes a subgroup com-
prising around 70% of patients with rheumatoid arthritis (RA) [1–3]. In this subset, disease is
strongly associated with HLA-DRB1 molecules containing a shared amino acid composition
(shared epitope) in the peptide binding groove [3,4]. With a relatively poor prognosis, more
erosive disease, and association with environmental factors such as smoking, ACPA-positive
RA differs from ACPA-negative RA [4–8]. ACPA-positive RA is usually diagnosed as a posi-
tive antibody reaction with a synthetic cyclic citrullinated peptide (CCP), the anti-CCP test.
ACPAs are highly specific for RA, even though the presence of citrullinated proteins in the
synovium also occurs in other inflammatory diseases [9].
Citrullination (deimination) refers to the posttranslational conversion of peptidylarginine
into peptidylcitrulline as catalyzed by peptidylarginine deiminases (PADs), of which five iso-
forms exist [10]. PAD2 and PAD4 are expressed in RA synovium and their presence correlates
with inflammatory markers [11–13]. Among the best described PAD substrates is fibrinogen,
which is present in the synovium of RA patients [14–18] together with numerous other citrul-
linated self-antigens including vimentin, alpha-enolase (ENO1), collagen type II and histones,
all of which have proposed pathogenic relevance [19–24]. PAD2 seems less restricted by the
amino acid composition surrounding the acceptor arginine residue than PAD4 [25]. Accord-
ing to some investigators, PAD2 citrullinates more arginine residues in fibrinogen than PAD4
[26], while others have reported that the two PAD isoforms citrullinate a similar number of
sites [27]. The two isoforms show similar dependency on calcium [27,28], reducing conditions
[29,30] and pH [27], and their cellular expression and function varies between different leuko-
cyte populations [31–33]. It is unclear if either isoform dominates in the generation of citrulli-
nated self-protein sites targeted by ACPAs. A recent study of 12 ACPA-positive RA patients
showed that in highly diluted serum, higher ACPA reactivity was found against fibrinogen
citrullinated by PAD4 than against fibrinogen citrullinated by PAD2 [34].
Isolated ACPAs react with citrullinated sites on multiple proteins[35,36], but non-overlap-
ping reactivities have also been demonstrated [35]. Several studies have examined the fine
specificity of ACPAs using citrullinated peptides, including some derived from fibrinogen,
ENO1, collagen type II and pro-filaggrin, and ACPAs from some individuals bind to several
sites whereas others react with only a single site [21,36,37]. PAD2-specific and PAD4-specific
inhibitors are currently under development for therapeutic use, and studies providing a better
understanding of their relative efficiency in generating citrullinated autoantigens are
warranted.
In this study, we aimed to determine the relative contributions by PAD2 and PAD4 to the
generation of antigenic determinants in full-length proteins targeted by ACPAs. To this end,
we examined the binding of autoantibodies from RA synovial fluid (SF) and plasma from 42
patients to in vitro citrullinated fibrinogen, ENO1, histone H3 and human serum albumin
(HSA), as well as to the native proteins.
Anti-citrullinated protein antibody-binding to PAD2/PAD4-citrullinated proteins
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Abbreviations: PAD, peptidylarginine deiminase;
ACPA, anti-citrullinated protein antibody; RA,
rheumatoid arthritis; CCP, cyclic citrullinated
peptide; ENO1, alpha.enolase; HSA, human serum
albumin.
Methods
Plasma and synovial fluid from RA patients
SF samples were obtained during knee joint aspiration from 10 anti-CCP-negative (median
anti-CCP: 3.6 U/ml [interquartile range: 2–11.4 U/ml]) and 32 anti-CCP-positive (878 U/ml;
[136–1353] U/ml) RA patients fulfilling the American College of Rheumatology criteria [38]
and characterised with respect to disease-activity, as assessed by DAS28. The majority of the
SF samples were also used in a recent study [12]. All SF samples were centrifuged at 1900 g for
10 min to remove cells and debris and stored at -80˚C until use. Plasma from all patients but
four was isolated from peripheral venous blood from the same patients at the time of arthro-
centesis. The study was approved by the local ethics committee of the Institute of Rheumatol-
ogy in Prague (No. 3294/2012), Czech Republic, and written informed consent was obtained
from all patients.
Serum anti-CCP antibodies and IgM-rheumatoid factor were determined by standard
ELISA kits (TestLine Clinical Diagnostics, Brunn, Czech Republic). Serum CRP was measured
using an immuno-turbidimetric technique with an Olympus biochemical analyser, model AU
400 (Olympus, Tokyo, Japan) and SF leukocytes were counted using the Iris IQ200 (Beckman
Coulter, CA, USA) analyzer.
In vitro citrullination
Recombinant human PAD2 and PAD4 were obtained from Cayman Chemicals (Michigan,
USA). Plasminogen-depleted fibrinogen (Merck Life Science, Hellerup, Denmark) was diluted
to 0.5 mg/mL in citrullination buffer (100 mM Tris-HCl, 1 mM DTT, 5 mM CaCl2, pH 7.5),
and incubated for 3 hours at room temperature (RT) with or without various concentrations
of PAD2 or PAD4. ENO1 (Antibodies-online, Aachen, Germany) and histone H3 (Sigma-
Aldrich, Copenhagen, Denmark) was diluted to 0.15 mg/mL in citrullination buffer, and HSA
(Statens Serum Institute, Copenhagen, Denmark) at 0.5 mg/mL, with or without 2 μg PAD per
mg protein.
ELISA for anti-citrullinated protein antibodies
Citrullinated or non-citrullinated proteins were diluted in coating buffer (30 mM Na2CO3, 70
mM NaHCO3, pH 9.6) and used for coating microtiter plates (Nunc, Roskilde, Denmark)
(100 μL/well) overnight at 4˚C. Plates were coated with fibrinogen at 5 μg/mL, whereas the
other proteins were used at a concentration of 10 μg/mL. To compensate for content of PAD2
or PAD4 in citrullinated samples, the enzymes were added to negative control wells devoid of
other proteins. Wells were washed thrice in PBS, 0.05% Tween-20, pH 7.4, and blocked in dilu-
tion buffer (PBS, 0.05% Tween-20, 2% bovine serum albumin). Plasma or SF was diluted in
dilution buffer, added to the wells, and incubated for 2 hours at room temperature (RT),
including a positive control, consisting of a SF pool, used for normalization. For determination
of ACPA cross-reactivity, SF was pre-incubated with the citrullinated proteins at 20, 100 and
200 μg/mL for 30 min before addition to the plates. After three washes, wells were incubated
with 100 μL horseradish peroxidase (HRP)-conjugated polyclonal rabbit anti-human immu-
noglobulin G (IgG) antibodies (P0214, Dako, Glostrup, Denmark) diluted 1:1000 in washing
buffer for 1 hour. Finally, the plates were washed three times in washing buffer and incubated
with 0.4 mg/mL o-phenylene-diamine (OPD; Kem-En-Tec; Taastrup, Denmark) in developing
buffer (35 mM citric acid, 65 mM Na2PO4, pH 5.0). After 10 min, the colour reaction was
stopped with 1.0 M H2SO4, and optical density (OD) was measured at 490–650 nm using the
SPECTROstar nano Microplate Reader (BMG Labtech). Data were processed using the MARS
Anti-citrullinated protein antibody-binding to PAD2/PAD4-citrullinated proteins
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software (BMG Labtech). To determine the specific binding of ACPAs, OD values obtained
from coating with native proteins were subtracted from the corresponding values obtained
with the citrullinated protein.
Western blotting
Gel-electrophoresis was performed with NuPAGE 10% Bis-Tris gels (Invitrogen, CA, USA)
using the NuPAGE1 system (Invitrogen) according to the manufacturer’s recommendations.
A second gel was stained in parallel with Coomassie Blue. Fibrinogen was loaded at 80 μg/mL
in reducing SDS buffer. Proteins were electro-blotted onto pre-activated Immobilon1-FL
polyvinylidene difluoride membranes (PVDF; Millipore) by tank-blotting. The membrane was
blocked in Odyssey Blocking buffer (LI-COR, Cambrigde, UK) for 1 hour under gentle shak-
ing at RT. An SF pool was diluted 1:100 in blocking buffer including 0.2% Tween-20 for 2
hours under gentle shaking at RT. The membrane was washed three times in TBS 0.2%
Tween-20 and incubated with rabbit anti-human IgG antibodies (A0424, Dako) for 1 hour
gently shaking at RT before another wash cycle. Finally, the membrane was incubated 1:15,000
with IRDye 800CW-conjugated goat anti-rabbit IgG antibody (LI-COR) in blocking buffer
including 0.2% Tween-20 for 1 hour under gentle shaking at RT. After a final wash cycle, the
membrane was washed in TBS and left for 1 hour in dark to dry. Membrane was imaged using
the Odyssey Fc infrared scanner (LI-COR).
Gel electrophoresis, western blotting, and densitometry to detect and quantify total protein
using brilliant blue G colloidal solution (Millipore-Sigma, St. Louis, USA) and protein citrulli-
nation using the anti-citrulline (modified) detection kit (Millipore-Sigma) were performed as
previously described [39].
Statistics
Wilcoxon matched-pairs signed rank test and Spearman’s correlation test were determined
using GraphPad Prism 7.02 (GraphPad Software, La Jolla, CA, USA). Statistical comparison
between PAD2- and PAD4- citrullinated proteins in AMC-blots were made using a paired t-
test. P-values < 0.05 were considered statistically significant.
Results
A direct ELISA was used to examine the binding of ACPAs contained in pooled SF from 6 RA
patients to native fibrinogen and fibrinogen citrullinated in vitro by PAD2 or PAD4. ACPA
binding was expressed as net binding, i.e. subtraction of signals obtained with native fibrino-
gen from signals obtained with citrullinated fibrinogen (Fig 1). ACPAs bound equally well to
PAD2-citrullinated and PAD4-citrullinated fibrinogen, irrespective of the PAD concentration
and SF dilution used (Fig 1A–1E). This observation was confirmed by Western blotting, which
showed that ACPAs bound to all three chains of fibrinogen (Fig 1F).
The preparations of PAD used in these experiments citrullinated fibrinogen efficiently over
a wide range of enzyme:substrate ratios (Fig 1G). When the amount of citrullinated fibrinogen
was normalized to total protein (Fig 1H), PAD2 appeared to citrullinate fibrinogen more effi-
ciently than PAD4 (Fig 1H).
Forty-two SF samples from RA patients were examined individually for autoantibody
reactivity against native, PAD2-citrullinated and PAD4-citrullinated fibrinogen (Fig 2A).
All samples contained very little reactivity against native fibrinogen and negligible reactivity
with PAD2 or PAD4 (S1 Fig). ACPAs from the majority of anti-CCP-positive samples
reacted with similar efficiency against PAD2-citrullinated and PAD4-citrullinated fibrino-
gen (Fig 2B). However, two patients showed more than two-fold higher ACPA-binding to
Anti-citrullinated protein antibody-binding to PAD2/PAD4-citrullinated proteins
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Fig 1. ACPA reactivity with PAD2- and PAD4-citrullinated fibrinogen. (A-D) Microtiter plates were coated with
native fibrinogen or fibrinogen citrullinated by either PAD2 or PAD4 (cit-Fib) at various concentrations. Pooled synovial
fluid (SF) from 6 anti-CCP-positive RA patients was applied at different dilutions ranging from 1:50 to 1:800, and the
binding of ACPAs was detected using HRP-anti-human IgG and OPD substrate. Shown are optical density (OD) values
from citrullinated minus native fibrinogen. (E) The pooled SF was also tested in dilutions of 1:5 and 1:15 using
fibrinogen citrullinated by 0.62 μg PAD per mg protein. Average and range of duplicate measurements are shown. (F)
Western blotting showing the binding of ACPAs from pooled SF (diluted 1:100) to native fibrinogen and fibrinogen
citrullinated by PAD2 or PAD4 (0.62 μg PAD per mg protein). Coomassie staining is shown as a loading control. The
three bands show α-chain, β-chain and γ-chain of fibrinogen. (G) Anti-modified citrulline (AMC) western blot to detect
citrullinated fibrinogen, citrullinated by 0.62 or 10 μg PAD per mg protein, respectively, (top) and brilliant blue stained
gel to detect total protein (bottom). (H) The density of the visible citrullinated protein bands in the AMC blot was
normalized to corresponding protein signal. Mean and SEM are shown for triplicate blots with p<0.05, p<0.01.
https://doi.org/10.1371/journal.pone.0203214.g001
Anti-citrullinated protein antibody-binding to PAD2/PAD4-citrullinated proteins
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PAD2-citrullinated than to PAD4-citrullinated fibrinogen (SF# 22 and 41), while two
patients showed the opposite pattern (SF# 37 and 38). Notably, 10 of the 32 SF samples from
anti-CCP positive patients contained very little or no ACPA-reactivity against fibrinogen
citrullinated by either PAD isoform. One SF sample from an anti-CCP-negative patient
(#3), on the other hand, contained as much reactivity against PAD2-citrullinated fibrinogen
as SF from most anti-CCP-positive patients.
We also tested plasma samples from 38 of the patients, with similar results (Fig 2C and 2D).
Association between ACPAs and disease activity
The reactivity of ACPAs against fibrinogen citrullinated by PAD2 correlated with patient dis-
ease activity, as measured by DAS28-ESR, and with inflammatory burden, measured as serum
CRP levels (Table 1). The correlation with DAS28-CRP was not significant, however (p = 0.15
for SF and p = 0.39 for plasma; data not shown). The binding of ACPAs to fibrinogen
Fig 2. Anti-citrullinated fibrinogen autoantibodies in SF and plasma from individual RA patients. IgG autoantibodies against native and citrullinated fibrinogen
were measured in (A, B) SF (diluted 1:50) and (C, D) plasma (diluted 1:50) from 32 anti-CCP-positive and 10 anti-CCP-negative RA patients using a direct ELISA based
on microtiter plates coated with native fibrinogen or fibrinogen citrullinated by either PAD2 or PAD4 (cit-Fib) at 0.62 μg PAD per mg protein. Shown are (A, C) raw
optical density (OD) values for all patients, and (B, D) net OD values all patients, adjusted for binding to native fibrinogen. Each data point represents duplicate
measurements. p<0.0001.
https://doi.org/10.1371/journal.pone.0203214.g002
Anti-citrullinated protein antibody-binding to PAD2/PAD4-citrullinated proteins
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citrullinated by PAD4 correlated with serum CRP levels and there was a trend towards correla-
tion with DAS28-ESR. As expected, the levels of antibodies against citrullinated fibrinogen
correlated strongly with serum anti-CCP levels, while no correlation was found with IgM
rheumatoid factor levels or leukocyte concentration in SF.
Autoantibody binding to native and citrullinated ENO1, histone H3 and
HSA
To examine the binding of ACPAs to proteins other than fibrinogen, ENO1, histone H3 and
HSA were citrullinated by PAD2 and PAD4 (Fig 3A–3C). PAD2 citrullinated ENO1 more effi-
ciently than PAD4, while histone H3 was most efficiently citrullinated by PAD4.
SF samples from 15 anti-CCP-positive RA patients were examined for antibody reactivity
against ENO1, histone H3 and HSA (Fig 4A–4C). A remarkably high antibody-reactivity was
observed against native ENO1 (Fig 4A) and, in some cases, against native histone H3 (Fig 4B).
No detectable binding to native HSA was observed (Fig 4C).
The binding of SF autoantibodies was increased for citrullinated ENO1 and histone H3,
compared to the native proteins (Fig 4A and 4B), while citrullination of HSA did not cause an
increase in antibody binding (Fig 4C). Binding to ENO1 citrullinated by PAD2 or PAD4 was
comparable, but in contrast, ACPAs showed preferential binding to histone H3 citrullinated
by PAD4 (Fig 4B).
ACPA binding to the citrullinated proteins was calculated for the 15 anti-CCP-positive and
9 anti-CCP negative RA patients. Notably, some patients who had no antibody reactivity
against citrullinated fibrinogen showed reactivity against citrullinated ENO1 or histone H3
(Fig 4D and 4E).
More binding to histone H3 was generally observed after citrullination with PAD4 than
with PAD2 (Fig 4E). In general, patients with high reactivity against one protein also showed
high reactivity against the other proteins, but exceptions were observed, e.g. #19 and #25 who
were only positive for citrullinated histone H3.
Determination of ACPA cross-reactivity
To assess cross-reactivity between ACPAs directed against PAD2- and PAD4-citrullinated
fibrinogen, we examined the ability of PAD2-citrullinated fibrinogen to compete for ACPA-
binding against PAD4-citrullinated fibrinogen and vice versa. As shown in Fig 5A and 5B,
incubation of SF with fibrinogen citrullinated by one PAD isoform strongly inhibited the bind-
ing of IgG antibodies to the other isoform, indicating that ACPAs generally do not discrimi-
nate between fibrinogen citrullinated by PAD2 and PAD4.
Table 1. Correlation between ACPA levels and disease parameters in 32 anti-CCP-positive RA patients.
DAS28-ESR CRP (mg/l) Anti-CCP (U/ml) RF Leukocyte/μl
Anti-cit-Fib (PAD2) SF rs = 0.37 p = 0.042 rs = 0.36 p = 0.041 rs = 0.58 p = 0.002 rs = 0.27 p = 0.13 rs = 0.02
p = 0.90
Anti-cit-Fib (PAD4) SF rs = 0.34 p = 0.06 rs = 0.41 p = 0.019 rs = 0.56 p = 0.001 rs = -0.18 p = 0.31 rs = 0.11
p = 0.55
Anti-cit-Fib (PAD2) Plasma rs = 0.33 p = 0.10 rs = 0.33 p = 0.083 rs = 0.58 p = 0.001 rs = 0.31 p = 0.11 rs = -0.17 p = 0.39
Anti-cit-Fib (PAD4) Plasma rs = 0.34 p = 0.085 rs = 0.39 p = 0.041 rs = 0.66 p = 0.0001 rs = 0.27 p = 0.16 rs = -0.10 p = 0.61
Cit-Fib (PAD2): Fibrinogen citrullinated by PAD2, cit-Fib (PAD4): Fibrinogen citrullinated by PAD4, SF: synovial fluid, CRP: C-reactive protein, ESR: Erythrocyte
sedimentation rate, RF: Rheumatoid factor. Spearman’s correlation coefficients (rs) and levels of significance are shown.
DAS28-ESR data was missing for four patients.
https://doi.org/10.1371/journal.pone.0203214.t001
Anti-citrullinated protein antibody-binding to PAD2/PAD4-citrullinated proteins
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In contrast, citrullinated ENO1 and citrullinated histone H3 showed little or no ability to
compete with citrullinated fibrinogen for ACPAs, irrespective of whether PAD2 or PAD4 was
used for citrullination (5A and 5B), suggesting a high degree of antigen-specificity. In agree-
ment, fibrinogen citrullinated by PAD2 or PAD4 showed modest or no ability to compete with
citrullinated ENO1 or histone H3 for ACPAs (data not shown).
Fig 3. In vitro citrullination of ENO1, histone H3 and HSA by PAD2 and PAD4. (A) ENO1, (B) histone H3 and (C) HSA were
citrullinated with PAD2 and PAD4 (2 μg PAD per mg protein). Western blots (upper panels) show citrullination, as detected by the AMC
kit, and gel electrophoresis followed by brilliant blue staining (lower panels) shows total protein. (D-F) The density of the visible bands
corresponding to citrullinated protein in the AMC blot was normalized to the total protein signal. Mean and SEM are shown for triplicate
blots, p<0.05.
https://doi.org/10.1371/journal.pone.0203214.g003
Anti-citrullinated protein antibody-binding to PAD2/PAD4-citrullinated proteins
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Discussion
PAD2 and PAD4 are present in the synovium of RA patients [11,40], but their individual roles
in generation of citrullinated self-antigens targeted by ACPAs is poorly understood. We have
here examined the binding of ACPAs to three proteins (fibrinogen, ENO1 and histone H3)
known to be antigens in RA, and to HSA, as a protein not reported to be antigenic, following
in vitro citrullination with PAD2 or PAD4.
When fibrinogen was used as antigen, autoantibodies from pooled SF from RA patients
reacted equally well with PAD2- and PAD4-citrullinated fibrinogen, at any SF dilution
employed and at any PAD concentration used for citrullination. These findings are not in
complete agreement with the findings of Blachére et al., who found that at high dilutions of
serum (1:250 or more), ACPAs bound better to PAD4-citrullinated fibrinogen than to PAD2--
citrullinated fibrinogen [34]. We used 1:50 dilutions of SF and plasma as standard, but
observed the same pattern at higher dilutions. Differences in the results of Blachére et al. and
ours may also have been caused by differences in the citrullination procedure [34], but both
studies showed a higher degree of citrullination of fibrinogen by PAD2 than by PAD4. Great
degree of overlap between fibrinogen sites citrullinated by PAD2 and PAD4 have been demon-
strated, although sites targeted by one PAD isoform, specifically, have also been described
[25,27]. Since PAD2-citrullinated fibrinogen competitively inhibited ACPA-binding to
PAD4-citrullinated fibrinogen and vice versa in this study, ACPAs seemingly do not show a
Fig 4. Binding of antibodies from RA patients to citrullinated and native proteins. Microtiter plates were coated
with native protein or protein citrullinated by either PAD2 or PAD4 (2 μg PAD per mg protein), and SF samples from
15 anti-CCP-positive RA patients were applied at a 1:50 dilution. Binding of IgG antibodies to native or citrullinated
(A) ENO1, (B) histone H3 and (C) HSA are shown as an average of duplicate optical density (OD) measurements, and
horizontal bars represent median values. (D) ACPA binding to citrullinated ENO1 and (E) histone H3 was calculated
for the 15 anti-CCP-positive RA patients and additional 9 anti-CCP-negative RA patients. Shown are averages and
range of duplicate OD measurements, after subtraction of signals obtained for native protein.
https://doi.org/10.1371/journal.pone.0203214.g004
Fig 5. ACPA cross-reactivity assessed by competitive ELISA. Microtiter plates were coated with fibrinogen citrullinated by either (A)
PAD2 or (B) PAD4 (2 μg PAD per mg protein). A pool of SF from three RA patients, diluted 1:50, was pre-incubated with increasing
concentrations of native fibrinogen, fibrinogen citrullinated by PAD2 (cit-Fib(PAD2)) or by PAD4 (cit-Fib(PAD4)), ENO1
citrullinated by PAD2 (cit-ENO1(PAD2)) or by PAD4 (cit-ENO1 (PAD4)), or histone H3 citrullinated with PAD2 (cit-H3(PAD2)) or
PAD4 (cit-H3(PAD4)) for 30 minutes before addition to the plates. Binding signals obtained in the absence of added protein (n = 7) are
shown as mean (solid line) and 95% CI (dotted line). The subsequent binding of IgG antibodies within the SF pool to (A)
PAD2-citrullinated fibrinogen or (B) PAD4-citrullinated fibrinogen, as determined by ELISA, are shown as mean ± SEM of duplicate
measurements.
https://doi.org/10.1371/journal.pone.0203214.g005
Anti-citrullinated protein antibody-binding to PAD2/PAD4-citrullinated proteins
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generalized preferential binding to fibrinogen citrullinated by either isoform. Moreover, citrul-
linated histone H3 and citrullinated ENO1 competed poorly with citrullinated fibrinogen for
ACPA binding and vice versa, supporting the notion that ACPAs are predominantly antigen-
specific. Using citrullinated fibrinogen and peptides derived from ENO1 and collagen type II,
Snir et al. also found no or modest ACPAs cross-reactivity [36]. However, another study
found that citrullinated peptides from filaggrin inhibited binding to intact citrullinated fibrin-
ogen, indicating that filaggrin and fibrinogen contain common epitopes [41]. Of note, we did
not observe ACPA binding to citrullinated HSA, indicating that not all citrullinated proteins
are targeted by ACPAs.
When SF samples from individual patients were examined, ACPAs from most patients
reacted equally well with fibrinogen citrullinated by PAD2 and PAD4, and the same was
observed with citrullinated ENO1. Notably, ACPAs from a few patients bound preferentially
to fibrinogen citrullinated by one isoform or the other. There was increased ACPA binding to
histone H3 citrullinated by PAD4. This may be explained by higher degree of citrullination by
PAD4. Moreover, due to its intranuclear location, PAD4 is thought to be the isoform responsi-
ble for citrullination of histone H3 in activated neutrophils [32,42,43]. However, it was shown
recently that PAD2 also citrullinates histone H3 upon release from stimulated neutrophils
[33]. Both isoforms may thus contribute to generation of target sites for ACPAs in histone H3
in vivo.
In this study, the binding of autoantibodies to native fibrinogen was negligible, but rela-
tively high autoantibody reactivity against native ENO1 was present. Some patients also had
autoantibodies against native histone H3. Other researchers have demonstrated binding of
autoantibodies to native proteins in RA, i.e. ENO1 and heterogeneous nuclear ribonucleopro-
teins A2/B1 [22,44]. Thus, measurement of antibodies to citrullinated proteins may include
signals that are caused by antibody-binding to native epitopes, but seemingly this is not the
case for fibrinogen. It is conceivable that breakage of tolerance by citrullinated sites in ENO1
and histone H3 leads to formation of autoantibodies targeting native sites via epitope spread-
ing. We have here focused on antibodies reacting with citrullinated epitopes, specifically.
In accordance with a well-established correlation between anti-CCP levels and disease
activity [6,45], we observed a link between high reactivity of ACPAs in SF against fibrinogen
citrullinated by either PAD isoform and high disease activity, expressed as DAS28-ESR or cir-
culating CRP levels.
Our study indicates that PAD2 and PAD4 are equally efficient at generating target sites for
ACPAs, at calcium concentration and pH comparable to those existing in in SF, where citrulli-
nation of fibrinogen presumably takes place [14,17,18]. Although the DTT used here as reduc-
ing agent may be stronger than physiological reductants, PAD2 and PAD4 have similar
activities at various redox conditions [29], so the results presented here are likely to reflect
their relative efficiencies in SF where both isoforms are present [32,40]. Due to differences in
intracellular and extracellular localization, on the other hand [32,33,42], PAD2 and PAD4 may
still play different roles in the pathogenesis of RA and other diseases.
Conclusions
PAD2 and PAD4 are both capable generating citrullinated epitopes in fibrinogen, ENO1 and
histone H3 recognized by ACPAs, while citrullinated HSA is not a target.
Supporting information
S1 Fig. Influence of anti-PAD antibodies in the measurement of ACPAs reacting with
citrullinated fibrinogen. IgG autoantibodies against PAD2- or PAD4-coated plates at the
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corresponding concentration to what is present in the preparations of citrullinated fibrinogen
(3 ng/mL). Shown are optical density (OD) values for all patients. Each data point represents
duplicate measurements.
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